ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,083.57
0.36%
Dow Jones
44,747.63
-0.28%
US Dollar vs MXN
20.4518
-0.62%
Brent Oil
74.175
-0.54%
Bitcoin
96,384.09
-0.25%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Caladrius Biosciences Inc (CLBS) Cotización

Caladrius Biosciences Inc

Caladrius Biosciences Inc (CLBS)

Celebrus Technologies Plc
0.4264
0.00
(0.00%)
Al cierre: 06 Febrero 3:00PM
Delayed by 15 minutes
0.4264
0.00
( 0.00% )
Fuera de horario: -
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
0.4264
Postura de Compra
0.4264
Postura de Venta
0.43
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
3.475M
Precio Anterior
0.4264
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
8,150,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.03
Beneficio por acción (BPA)
-2.56
turnover
-
Beneficio neto
-20.84M

Acerca de Caladrius Biosciences Inc

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the... Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its current product candidates include XOWNA, HONEDRA and CLBS201. Mostrar más

Sector
Health & Allied Services,nec
Industria
Insurance Carriers, Nec
Sitio web
www.caladrius.com
Sede
Wilmington, Delaware, USA
Fundado
2006

CLBS Últimas noticias

Más noticias

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens...

15 Septiembre 2022
GlobeNewswire Inc.

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified...

14 Septiembre 2022
GlobeNewswire Inc.

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual...

12 Septiembre 2022
GlobeNewswire Inc.

Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing...

08 Septiembre 2022
GlobeNewswire Inc.

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius’ initial...

10 Agosto 2022
GlobeNewswire Inc.

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins...

04 Agosto 2022
GlobeNewswire Inc.

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

BASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

02 Agosto 2022
GlobeNewswire Inc.

Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

28 Julio 2022
GlobeNewswire Inc.

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company...

06 Julio 2022
GlobeNewswire Inc.

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

09 Junio 2022
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CLBS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Caladrius Biosciences?
El precio actual de las acciones de Caladrius Biosciences es US$ 0.4264
¿Cuántas acciones de Caladrius Biosciences están en circulación?
Caladrius Biosciences tiene 8,150,000 acciones en circulación
¿Cuál es la capitalización de mercado de Caladrius Biosciences?
La capitalización de mercado de Caladrius Biosciences es USD 3.48M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Caladrius Biosciences?
Caladrius Biosciences ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Caladrius Biosciences?
El ratio precio/beneficio de Caladrius Biosciences es -1.03
¿Cuál es la moneda de reporte de Caladrius Biosciences?
Caladrius Biosciences presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Caladrius Biosciences?
El último beneficio anual de Caladrius Biosciences es USD -20.84M
¿Cuál es la dirección registrada de Caladrius Biosciences?
La dirección registrada de Caladrius Biosciences es 651 N BROAD ST SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19709
¿Cuál es la dirección del sitio web de Caladrius Biosciences?
La dirección del sitio web de Caladrius Biosciences es www.caladrius.com
¿En qué sector industrial opera Caladrius Biosciences?
Caladrius Biosciences opera en el sector INSURANCE CARRIERS, NEC

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
LTRYLottery com Inc
US$ 1.98
(40.43%)
8.22M
NCEWNew Century Logistics BVI Ltd
US$ 2.61
(37.37%)
1.63M
MGOLMGO Global Inc
US$ 0.233
(25.95%)
24.32M
FARMFarmer Brothers Company
US$ 2.25
(25.00%)
88.21k
PWMPrestige Wealth Inc
US$ 1.34
(18.58%)
562.92k
STIMNeuronetics Inc
US$ 2.80
(-21.35%)
147.8k
NKLANikola Corporation
US$ 0.5943
(-21.02%)
4.1M
RNXTRenovoRx Inc
US$ 1.1601
(-20.54%)
38.46k
LTRXLantronix Inc
US$ 3.5005
(-16.65%)
103.66k
LYTLytus Technologies Holdings PTV Ltd
US$ 0.29
(-14.40%)
3.03M
MGOLMGO Global Inc
US$ 0.233
(25.95%)
24.32M
AMZNAmazon.com Inc
US$ 231.72
(-2.98%)
11.83M
LTRYLottery com Inc
US$ 1.98
(40.43%)
8.22M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1221
(-10.88%)
5.9M
NVDANVIDIA Corporation
US$ 128.47
(-0.16%)
4.71M

Discusión

Ver feed completo
RIGATONI RIGATONI 3 minutos hace
.25 gap above hit, enjoy ~Rig
Dabeav Dabeav 3 minutos hace
Schwab updated: $6.85+$0.8700(+14.55%)
Post-market: 5:00:03 PM ET, 02/06/2025
$6.85+$0.8700(+14.55%)
At close: 4:00:00 PM ET, 02/06/2025
Bid
$6.32
Ask
$6.93
Bid/Ask Size
-/-
Previous close
$5.98
Today's open
$
FNMA
Slojab Slojab 4 minutos hace
Expenses
General and administrative 590,871 ....... 299,117
Employee compensation and benefits 361,075 ....... 195,452
Professional fees & consulting 942,740 ....... 6,780
Total Expenses 1,894,686 ....... 501,349

Mortgage note payable 26,800,000 versus 18,0
CBRF
B402 B402 4 minutos hace
Medicare and Medicaid 1965,,,,,,,,,,SS 1935.....

After that, history will record dems turned their backs on the American worker....
janice shell janice shell 5 minutos hace
LOLOLOL!! That store has nerve, attaching a "sale" sign:

https://x.com/acnewsitics/status/1887561926076424443
DewDiligence DewDiligence 5 minutos hace
You might be just a little biased, LOL.
DE
crazy horse 0 crazy horse 0 5 minutos hace
Stickied News RITE] Announces Definitive Agreement Acquiring Subsidiaries Holding $432 Million in Audited Asset Value

MINERALRITE Corporation [Symbol: RITE] Announces Definitive Agreement Acquiring Subsidiaries Holding $432 Million in Audited Asset Value and Potential Sizable Addition
RITE
learningcurve2020 learningcurve2020 5 minutos hace
That IS a big day around here!

I see the mod deleted my post about my not lying.
NWBO
timberwolf7 timberwolf7 5 minutos hace
assuming you meant a SCREEN SHOT:

I haven't figured out how to post an image on here yet based on my
account level?? But it looked like this:

TNXP
NON-Marginalized 1/10th of the shares in the account
MARGINALIZED 9/10ths of the shares in the
TNXP
janice shell janice shell 6 minutos hace
Excellent reporting by the Guardian. ICE is beyond slimy. As is Trumpty:

https://www.theguardian.com/us-news/2025/feb/06/ice-us-immigration-deportations-google
CrazyC CrazyC 6 minutos hace
NCEW - Those 13-Gs are just folks registering their shares from the IPO...

See page 92...

https://www.sec.gov/ix?doc=/Archives/edgar/data/1968043/000149315225003986/form20-f.htm
NCEW
back2basics back2basics 7 minutos hace
Cap, Toby wrote that song in the aftermath of 9 - 11. Peter Jennings, a Canadian was putting together a TV show, dedicated to tha tragic day. He invited Toby too appear in the show, but told he couldn't sing Courtesy of Red White and Blue. It was |too violent."

Toby refused t appe
EmpressMonk25 EmpressMonk25 7 minutos hace
Imagine all the money you missed out on shorting that one? :-)
HMBL
pual pual 7 minutos hace
I did talk to him once but thereafter I did not feel I knew much more than before. In any case I believe that if he wanted his shareholders to know more he would issue a NR or PR but it is obvious that for the moment he does not intend to open up and doing it secretely on the phone would not be that
GRST
crazy horse 0 crazy horse 0 8 minutos hace
RITE] Announces Definitive Agreement Acquiring Subsidiaries Holding $432 Million in Audited Asset Value

MINERALRITE Corporation [Symbol: RITE] Announces Definitive Agreement Acquiring Subsidiaries Holding $432 Million in Audited Asset Value and Potential Sizable Additional Mineral Res
RITE
I am done I am done 9 minutos hace
$RITE Announces Acquisition Definitive Agreement
https://www.newsfilecorp.com/release/239914
RITE
wickerman wickerman 9 minutos hace
$CLEU another R/S 1:80 hope you exited this scam.

https://www.sec.gov/Archives/edgar/data/1775085/000147793225000769/cleu_ex991.htm
CLEU
I am done I am done 10 minutos hace
$RITE Announces Acquisition Definitive Agreement
https://www.newsfilecorp.com/release/239914
RITE
jtomm jtomm 10 minutos hace
FARM - I remember looking at this in the early 2000's and it just looked like a perfect growth stock. I think it was Roy Farmer running the show back then. Sort of stopped following the company. Was it mainly transitioning to new mgt that caused all the problems from what you know?
ScottishTexan ScottishTexan 10 minutos hace
This one is still trading? Unbelievable.
PPCBD
WinstonCup WinstonCup 10 minutos hace
Inspector gadget is number 1 pumper here since L45 left.
WDLF

Su Consulta Reciente

NASDAQ
CLBS
Caladrius Biosciences
BIT
F33214
Vontobel Financial Produ...
BIT
UC3U4A
Unicredit Bank
BIT
UC2RT0
Unicredit Bank
BIT
F34636
Vontobel Financial Produ...
BIT
VGGLBD
Global Bond Classe L
BIT
F39000
Vontobel Financial Produ...
BIT
S27188
Societe Generale Effekten
AQSE
MCAP
Macaulay Capital
BIT
IJPE
Exchange Trading Funds
BIT
EJP3
ETFS 3x Long JPY Short EUR
COIN
NFTBUST
NFTB
BIT
UB25VN
UniCredit Bank
LSE
TRN
Trainline
BIT
UC1H1W
Unicredit Bank
BIT
F16990
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios